Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized phase III trial to compare radiation therapy alone with radiation therapy and concomitant anti-EGFr antibody (C225) for locally advanced squamous cell carcinomas of the head and neck

Next Previous
X
Search
Trial Profile

Randomized phase III trial to compare radiation therapy alone with radiation therapy and concomitant anti-EGFr antibody (C225) for locally advanced squamous cell carcinomas of the head and neck

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 28 Dec 2015 Retrospective results published in the Journal of Clinical Oncology.
    • 01 Jan 2010 Five-year survival data published in Lancet Oncology.
    • 23 Sep 2008 Updated 5-year overall survival data have been presented at the 2008 American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting in Boston.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top